About BLCM

Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

BLCM is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
ITOT iShares Core S&P Total U.S. Stock Market ETF 20.4 B 2.04474E+10 3,545 3545 0.0% 0 81 K 81120
IWC iShares Microcap ETF 858.7 M 8.58676E+08 1,430 1430 0.02% 0.0002 183 K 182979
IWM iShares Russell 2000 ETF 41.2 B 4.12382E+10 1,985 1985 0.0% 0 1.6 M 1552160
IWN iShares Russell 2000 Value ETF 8.5 B 8.54849E+09 1,351 1351 0.0% 0 224 K 223606
IWO iShares Russell 2000 Growth ETF 8.9 B 8.9462E+09 1,230 1230 0.01% 0.0001 443 K 442653
IWV iShares Russell 3000 ETF 9.3 B 9.30666E+09 2,929 2929 0.0% 0 17 K 17275
URTY ProShares UltraPro Russell2000 90.2 M 9.0207E+07 1,996 1996 0.0% 8.50701E-06 3 K 2521
UWM ProShares Ultra Russell2000 162.4 M 1.62362E+08 1,996 1996 0.0% 1.46671E-05 5 K 5186